Literature DB >> 25041231

Societal economic benefits associated with an extended-release opioid with abuse-deterrent technology in the United States.

Noam Y Kirson1, Amie Shei, Alan G White, Howard G Birnbaum, Rami Ben-Joseph, Louis F Rossiter, Edward Michna.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25041231     DOI： 10.1111/pme.12489

Source DB:  PubMed          Journal:  Pain Med        ISSN： 1526-2375            Impact factor:   3.750


× No keyword cloud information.
  5 in total

1.  Technology: Barriers to misuse.

Authors:  Elie Dolgin
Journal:  Nature       Date:  2015-06-25       Impact factor: 49.962

2.  The health insurance industry: perpetuating the opioid crisis through policies of cost-containment and profitability.

Authors:  Michael E Schatman; Lynn R Webster
Journal:  J Pain Res       Date:  2015-03-18       Impact factor: 3.133

3.  Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) versus Extended-Release Morphine Administered Orally in Nondependent Recreational Opioid Users.

Authors:  Michael D Smith; Lynn R Webster; John Lawler; Karsten Lindhardt; Jeffrey M Dayno
Journal:  Pain Med       Date:  2017-05-01       Impact factor: 3.750

4.  Next-generation sequencing of human opioid receptor genes based on a custom AmpliSeq™ library and ion torrent personal genome machine.

Authors:  Dario Kringel; Jörn Lötsch
Journal:  Clin Chim Acta       Date:  2016-10-08       Impact factor: 3.786

Review 5.  Mitigation of IV Abuse Through the Use of Abuse-Deterrent Opioid Formulations: An Overview of Current Technologies.

Authors:  Richard L Rauck
Journal:  Pain Pract       Date:  2019-02-28       Impact factor: 3.183
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.